Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28388489 | 1.00 | CMA1 (0.48) | CMA1MAPK1F2PRSS1ELANE | |
| SCHEMBL23863881 | 1.00 | CMA1 (0.48) | CMA1MAPK1F2PRSS1ELANE | |
| SCHEMBL28394567 | 0.92 | F2 (0.56) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL24447150 | 0.92 | F2 (0.56) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL16706511 | 0.92 | F2 (0.56) | CMA1F2PRSS1ACECTRC | |
| SCHEMBL16703018 | 0.90 | ELANE (0.45) | MAPK1F2ELANEACE | |
| SCHEMBL20859022 | 0.89 | CMA1 (0.58) | CMA1ELANECTRC | |
| SCHEMBL28390853 | 0.89 | CMA1 (0.58) | CMA1ELANECTRC | |
| SCHEMBL18103339 | 0.89 | CMA1 (0.58) | CMA1ELANECTRC | |
| SCHEMBL23863946 | 0.89 | F2 (0.52) | CMA1F2PRSS1ACECTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516023-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2026-01-06 | — | — | US | disclosed |
| CN-111187202-B | NMDA antagonist prodrugs | 阿斯利康(瑞典)有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4001272-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2024-11-13 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001272-A1 | NMDA ANTAGONIST PRODRUGS | Astrazeneca AB (SE) | 2022-05-25 | — | — | EP | disclosed |
| EP-3564234-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-09-29 | — | — | EP | disclosed |
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| US-10815199-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2020-10-27 | — | — | US | disclosed |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-05-23 | — | — | US | disclosed |
| EP-3066091-B1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-10207994-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2019-02-19 | — | — | US | disclosed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2018-02-08 | — | — | US | disclosed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-9822075-B2 | NMDA antagonist prodrugs | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2016-09-29 | — | — | US | disclosed |
| WO-2015067923-A1 | NMDA ANTAGONIST PRODRUGS | ASTRAZENECA AB (SE) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040039-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
| US-10815199-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
| US-10207994-B2 | NMDA antagonist prodrugs | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
| US-20190152914-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
| US-20160280647-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
| US-20180037550-A1 | NMDA ANTAGONIST PRODRUGS | GRIN1, GRIN2A, GRIN3A | CMA1 4742/4885MAPK1 1508/4885F2 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.